Date: 2019-10-28
Type of information: Nomination
Compound:
Company: 20Med Therapeutics (NL)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- On October 28, 2019, 20Med Therapeutics BV, a biotechnology company developing innovative nanoparticles for delivery of RNA therapeutics announced the appointment of Dutch biotech veteran and serial entrepreneur Allard Kaptein to its Supervisory Board.
Dr. Allard Kaptein is Managing Director of Genase Therapeutics. Prior to that, he was co-founder of Acerta Pharma, spinning out the covalent BTK inhibitor series from MSD into Acerta Pharma, which resulted in the now FDA approved drug acalabrutinib in 2017. Dr. Kaptein is an expert in Drug Discovery and in translating science from bench to clinic and from the clinic back to identification of new targets and understanding of mechanism of action. In total, he has over 25 years’ experience in the pharmaceutical industry in Oncology, Autoimmune Diseases, and Cardiovascular Diseases. He held various positions of increasing responsibilities at Glaxo(Wellcome), Organon, Schering Plough, and MSD.
Dr. Kaptein holds a PhD in Biopharmaceutical Sciences from the University Leiden, with studies performed at the Gaubius Institute TNO in Leiden, The Netherlands.
Financial terms:
Latest news:
Is general: Yes
